Sustainability & Community Benefit Sharing

Crofelemer is extracted and purified from sangre de grado, the bark sap of the Croton lechleri tree, which is an abundant, fast-growing Amazonian pioneer tree species widespread in Colombia, Ecuador, Peru, and Bolivia and is used by traditional healers working with medicinal plants in these areas. The bark sap, also known as latex, is sustainably harvested utilizing fair trade practices by local peoples who have been collaborating with our subsidiary Napo Pharmaceuticals and our local partners over the past two decades with the aim of ensuring a high degree of quality and ecological integrity. Napo’s sustainable harvesting programs have a benefit of sequestering CO2.

Learn about the deep commitment Jaguar Health’s employees have to social responsibility.

Healing Forest Conservancy

The Healing Forest Conservancy (HFC) is an independent non-profit foundation established in 1990 to specifically develop and implement a process to return benefits from product profits to collaborating countries and cultural groups after a product is commercialized, and for as long as Napo has a profit. These long-term benefits will be a percentage of all Napo’s products profits.

The mission of the HFC is to promote the conservation of the biological diversity of tropical forests, particularly medicinal plants, and the survival of the cultural diversity of tropical forest peoples, particularly their traditional knowledge of medicinal plants. The Conservancy will distribute these long-term benefits, equally, to all the countries and cultures that are Napo collaborators worldwide, regardless of where the plant sample or traditional knowledge originated. Trust funds are the financial mechanisms through which long-term revenues will be disbursed to the participating communities, regardless of the origin of the product.

MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information